TOSCCAA-TXA Trial

We are conducting research in Cerebral Amyloid Angiopathy (CAA) called the TOSCCAA TXA trial.

This research study is evaluating the safety and feasibility of the medication tranexamic acid in reducing the risk of recurrent bleeding in patients with cerebral amyloid angiopathy (CAA).

Currently, there are no approved medications to prevent further bleeding in patients with CAA. This study will help researchers understand if this particular study medication can reduce the risk of bleeding without the increasing risk of serious side effects.

We are looking for participants who have had a diagnosis of CAA and a recent brain bleed in the last 6 months to join the study.

See the page on the Stroke Foundation website for further details: https://strokefoundation.org.au/what-we-do/research/research-projects/reducing-risk-of-further-bleeding-in-cerebral-amyloid-angiopathy-caa